Onivyde plus talazoparib or temozolomide for resistant solid tumors
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age at enrollment must be over 12 months and under 30 years.
- You must have a hard-to-cure (refractory or recurrent) cancer that cannot be treated with curative surgery/therapy.
- For Ewing sarcoma studies: your tumor must have an EWSR1-FLI1 fusion or another EWS gene rearrangement.
- You must have cancer that can be measured or at least evaluated on scans/tests (bone-only disease may not count for some outcome goals).
- You must be recovered from prior treatments and have adequate blood counts, kidney function, liver function, and oxygen/breathing status.
- If you could become pregnant: you must have a negative pregnancy test and use effective birth control during treatment and for months after the last dose; pregnancy or breastfeeding is not allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial compares two different chemo combinations for Ewing's sarcoma that has not responded to first-line treatment. One group gets a special liposomal form of irinotecan plus temozolomide and vincristine; the other gets standard irinotecan with the same two drugs. The goal is to see which is safer and more effective.
Hear when a new Recurrent Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.